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Inhibition of IGF-1R-dependent PI3K
activation sensitizes colon cancer cells
specifically to DR5-mediated apoptosis
but not to rhTRAIL
Bodvael Pennarun a,b, Jan H. Kleibeuker b, Tjitske Oenema a, Janet H. Stegehuis a,
Elisabeth G.E. de Vries a and Steven de Jong a,∗
a Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen,
The Netherlands
b Department of Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen,
The Netherlands
Abstract. Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) initiates apoptosis in tumor cells upon
binding to its cognate agonistic receptors, death receptors 4 and 5 (DR4 and DR5). The activity of the insulin-like growth factor 1
(IGF-1) survival pathway is often increased in cancer, influencing both cell proliferation and apoptosis. We hypothesized that
inhibiting the IGF-1 receptor (IGF-1R) using NVP-AEW541, a small molecular weight tyrosine kinase inhibitor of the IGF-1R,
could increase death receptor (DR)-mediated apoptosis in colon cancer cells.
Methods: The analyses were performed by caspase assay, flow cytometry, Western blotting, immunoprecipitation and fluores-
cent microscopy.
Results: Preincubation with NVP-AEW541 surprisingly decreased apoptosis induced by recombinant human TRAIL
(rhTRAIL) or an agonistic DR4 antibody while sensitivity to an agonistic DR5 antibody was increased. NVP-AEW541 could in-
hibit IGF-1-induced activation of the phosphatidylinositol 3-kinase (PI3K) pathway. The effects of the PI3K inhibitor LY294002
on TRAIL-induced apoptosis were similar to those of NVP-AEW541, further supporting a role for IGF-1R-mediated activation
of PI3K. We show that PI3K inhibition enhances DR5-mediated caspase 8 processing but also lowers DR4 membrane expres-
sion and DR4-mediated caspase 8 processing. Inhibition of PI3K reduced rhTRAIL sensitivity independently of the cell line
preference for either DR4- or DR5-mediated apoptosis signaling.
Conclusions: Our study indicates that individual effects on DR4 and DR5 apoptosis signaling should be taken into considera-
tion when combining DR-ligands with PI3K inhibition.
Keywords: DR4, DR5, TRAIL, PI3K, colon cancer
1. Introduction
Colorectal cancer (CRC) is the second leading cause
of cancer-related deaths in western countries. Despite
improvements in the area of prevention and treatment,
mortality remains high because of the frequent pres-
ence of distant metastases at the time of diagnosis. To-
gether with novel chemotherapies and liver surgery, it
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is estimated that targeted agents such as cetuximab and
bevacizumab have improved the 5-year overall survival
for patients with metastatic CRC to more than 30% [7,
25]. This supports the development of novel targeted
treatment options, including agents that activate the
TRAIL apoptotic pathway [12,17,39].
The TRAIL apoptotic pathway is initiated by tu-
mor necrosis factor-related apoptosis-inducing ligand
(TRAIL), a type II transmembrane protein of the tumor
necrosis factor superfamily. TRAIL binds to cell sur-
face homo- and/or heterotrimers of death receptors 4
and 5 (DR4 and DR5), thus triggering the “caspase cas-
cade” [23]. The extracellular domain of TRAIL can be
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processed proteolytically, leading to the release of a
soluble trimeric form of TRAIL with similar proapop-
totic properties [36,50]. The potential of the TRAIL
apoptotic pathway as a target to treat cancer was first
established when soluble recombinant human TRAIL
(rhTRAIL) was found to selectively induce apoptosis
in tumor cells without serious toxicity to normal tis-
sues [1,45]. Several other agents that target the two
death receptors have been engineered since the discov-
ery of the TRAIL apoptotic pathway. So far, this path-
way can be activated by rhTRAIL, by mutant forms
of TRAIL which bind preferentially to either DR4 or
DR5 homotrimers [22,28,42] and by agonistic mon-
oclonal antibodies also designed to bind specifically
DR4 or DR5 [4,13,20,37]. The potential of the TRAIL
receptors as therapeutic targets is underscored by the
fact that their expression and sensitivity have both been
shown to increase during CRC tumor progression [15,
24]. Although the sensitivity of tumor cells to TRAIL-
induced apoptosis is heterogeneous as a result of in-
trinsic or acquired resistance, combination therapies to
overcome this phenomenon are already under investi-
gation (for review see [21,35]).
Numerous growth factor receptor pathways are al-
tered in CRC cancer, influencing gene expression, cell
proliferation and apoptosis [5]. Some of these path-
ways constitute interesting targets for drugs that could
be combined with rhTRAIL [6,30,34]. The insulin-like
growth factor (IGF) signaling pathway is involved in
the growth and development of many tissues, and plays
a crucial role in the normal functioning of the organ-
ism [26]. IGF signaling cascades begin at the cell sur-
face with IGF ligands (IGF-1 and -2) binding to several
transmembrane receptors, namely IGF-1R, IGF-2R
and the insulin receptor (IR). Downstream from these
receptors, mitogen-activated protein kinase (MAPK)
and phosphatidylinositol 3-kinase (PI3K)/Akt path-
ways are stimulated [26]. Diverse cellular responses
such as gene expression, cell proliferation and apop-
tosis suppression are induced, thus promoting cell sur-
vival. Importantly, the IGF system is frequently dereg-
ulated in CRC cancers [2,26], more than 90% of which
express IGF-1R while normal colonic mucosa does not
show substantial expression levels [48].
The downstream PI3K/Akt receives signals not only
from the IGF-1R but also from human epidermal
growth factor receptor (HER) family receptors such as
HER-2 and epidermal growth factor receptor (EGF-R)
[19,53], which can also promote carcinogenesis when
deregulated. Furthermore, alterations in the PI3K/Akt
signaling itself have been found in many forms of can-
cer and can originate at multiple levels of the cas-
cade [27,49]. For these reasons, the PI3K/Akt path-
way holds promise as a target for cancer treatment.
Clinical trials are being carried out with blocking an-
tibodies that target IGF-1R, and also with kinase in-
hibitors targeting IGF-1R or PI3K [14,51]. In this
context, we investigated whether inhibiting the IGF-
1R survival pathway, and more specifically its down-
stream PI3K/Akt pathway, could functionally increase
rhTRAIL-induced apoptosis.
We tested the effects of the IGF-1R inhibitor NVP-
AEW541 [31] on TRAIL sensitivity in SW948,
a colon cancer cell line and in SW948-TR, the TRAIL-
resistant sub-line. Furthermore, we investigated
whether sensitivity to agonistic DR4- or DR5-specific
monoclonal antibodies was differentially affected by
NVP-AEW541. We analyzed the effects of LY294002,
an inhibitor of the downstream PI3K/Akt pathway
[46], on the sensitivity to these various activators
of TRAIL-mediated cell death. Finally, we validated
these findings in another colon carcinoma cell line,
Colo205.
2. Materials and methods
2.1. Reagents
rhTRAIL was produced non-commercially follow-
ing a protocol described previously [1]. The agonis-
tic anti-DR4 (HGS-ETR1) and anti-DR5 (HGS-TR2J)
antibodies were a donation from Human Genome
Science (HGS, Rockville, MD, USA). The TRAIL-
receptor antibodies used for flow cytometry experi-
ments were obtained from Immunex corporation (Seat-
tle, WA, USA). NVP-AEW541 was kindly provided by
Novartis Pharma AG, Basel, Switzerland. LY294002
was purchased from Cell Signaling Technology, Lei-
den, The Netherlands. The ZB ActiveFluor Caspase 3/7
kits were obtained from Zebra Bioscience, Enschede,
The Netherlands. 3-(4,5-dimethyl-thiazol-2-yl) 2,5-di-
phenyltetrazolium bromide (MTT)-solution was pur-
chased from Sigma-Aldrich Chemie BV (Zwijndrecht,
The Netherlands).
2.2. Cell lines
The TRAIL-sensitive colon carcinoma cell line
SW948 was purchased from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA) and
cultured as described previously [43]. The TRAIL-
resistant sub-cell line SW948-TR was made as de-
scribed previously [44].
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Colo205 colon carcinoma and MCF7 breast carci-
noma cell lines were purchased from the ATCC and
grown in RPMI containing 10% FCS at 37◦C in a hu-
midified atmosphere with 5% CO2.
2.3. Cytotoxicity assay
A microculture tetrazolium (MTT) assay was used
to determine cytotoxicity. SW948 and SW948-TR cells
were incubated in a total volume of 200 µl. Treatment
consisted of continuous incubation with various con-
centrations of NVP-AEW541 for 96 h. Assays were
performed as described before [43].
2.4. Flow cytometry
Cells were stained for TRAIL-receptor membrane
expression as described previously [43] and analyzed
with a Epics Elite flow cytometer (Coulter Electronics,
Hialeah, FL, USA). Membrane expression was mea-
sured as the increase in mean fluorescence intensity of
the whole analyzed cell population.
To determine surface expression of IGF-1R, a sim-
ilar protocol was used. Cells were stained for 45 min
on ice with phycoerythrin (PE)-conjugated anti-human
IGF-1Rα or PE-conjugated mouse IgG1 as an isotype
control (BD Pharmingen, Alphen aan den Rijn, The
Netherlands). After two washes a minimum of 5,000
cells was analyzed by flow cytometry.
2.5. Caspase 3/7 activity assay
Caspase 3/7 activity was assayed using the caspase-
specific fluorescence peptide substrate DEVD-MCA
according to the manufacturer’s instructions (Zebra
Bioscience BV, Groningen, The Netherlands). A Brad-
ford assay was used to normalize protein concen-
trations between samples. Fluorescence from free 7-
amino-4-trifluoromethyl coumarin was monitored in
a FL600 Fluorimeter Bio-tek plate reader (Beun de
Ronde, Abcoude, The Netherlands) using 340 nm ex-
citation and 460 nm emission filters.
2.6. SDS-polyacrylamide gel electrophoresis and
Western blotting
Sample preparation and Western blot analysis were
performed as described previously [43]. Proteins were
detected with the following antibodies: mouse-anti-
FADD from Transduction Laboratories (Lexington,
KY, USA), mouse anti-caspase 8 from Cell Signaling
Technology (Leusden, The Netherlands) and mouse
anti-actin from ICN Biomedicals (Zoetermeer, The
Netherlands). Mouse-anti-FLIP NF6 was kindly pro-
vided by Dr. M. Peter (University of Chicago, IL,
USA). The secondary antibodies were labeled with
horseradish peroxidase (HRP) (DAKO, Glostrup, Den-
mark), and chemiluminescence was detected using
the BM-chemiluminescence kit or with the Lumi-
Light Plus Western blotting kit (Roche Diagnostics,
Mannheim, Germany). A slightly modified lysis proto-
col was used to investigate Akt, MAPK44/42, phospho-
MAPK44/42 and phospho-Akt (ser473) protein levels.
Briefly, cells were seeded in 6-well plate and serum-
starved for 24 h before 1 h treatment with NVP-
AEW541 (500 nM). Cells were then stimulated for
15 min with recombinant human IGF-1 (R&D sys-
tems Europe Ltd, Abingdon, UK). Next, cells were
washed once with cold PBS, lysed in 100 µl cold SDS
sample buffer (62.5 mM Tris-HCl pH 6.8, 2% w/v
SDS, 10% glycerol, 50 mM DTT) and boiled in a wa-
ter bath for 5 min. Protein concentrations were de-
termined using the DC protein assay (Biorad Labo-
ratories BV, Veenendaal, The Netherlands). Western
blot analysis was performed as described previously.
A similar protocol was used to investigate the effects
of LY294002 on Akt phosphorylation. Briefly, cells
were cultured in medium with 10% FCS for 24 h be-
fore 1 h-treatment with 10 or 20 µM LY294002 and
subsequent harvesting, using the methods described
above. To detect Akt and phospho-Akt, the follow-
ing antibodies were used: rabbit anti-Akt and rab-
bit anti-phospho-Akt (ser473) from Cell Signalling
Technology, Leiden, The Netherlands. MAPK44/42 and
phospho-MAPK44/42 (Thr202/Tyr204) were detected
using rabbit anti-MAPK44/42 from Santa Cruz and
mouse anti-phospho-MAPK44/42 from Cell Signalling
Technology, Leiden, The Netherlands.
2.7. DR5-DISC isolation
Briefly, 50 × 106 cells per condition were grown in
medium harvested and resuspended in fresh medium.
Cells were stimulated with 5 µg/ml HGS-TR2J in a
final volume of 2 ml. The antibodies were added af-
ter cell lysis for the control treatment. Cell suspen-
sions were incubated for 15 min at 37◦C and the
reaction was stopped by the addition of 10 ml ice-
cold phosphate buffered saline (PBS). The cells were
immediately washed with ice-cold PBS and lysed in
1 ml lysis buffer (20 mM Tris-HCl, pH 7.5, 150
mM NaCl, 0.2% Nonidet P-40, 10% glycerol, 1 mM
phenylmethylsulfonyl fluoride) with complete protease
inhibitors (Roche Diagnostics, Almere, The Nether-
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lands) for 30 min on ice. After centrifugation (12,000×
g) at 4◦C for 10 min, the lysates were pre-cleared
with 20 µl Sepharose-6B (Pharmacia, Uppsala, Swe-
den) for 2 h at 4◦C and immunoprecipitated with
50 µl protein-G agarose beads (Roche Diagnostics,
Mannheim, Germany) for 3 h at 4◦C. Beads were
washed twice with 1 ml lysis buffer and once with PBS
before re-suspension in standard Western blot sample
buffer and boiling for 5 min. Immunoprecipitated pro-
teins were separated with SDS-PAGE. Western blot
analysis for FADD and c-FLIP was performed as de-
scribed above. DR5 was detected using rabbit anti-
DR5 from ProSci Inc. (Poway, CA, USA). Caspase 8
was detected with rabbit anti-caspase 8 (Abcam plc,
Cambridge, UK). Anti-rabbit and anti-mouse HRP-
conjugated secondary antibodies were used for signal
detection (DAKO, Glostrup, Denmark).
2.8. Propidium iodide staining
Staining was performed according to Nicoletti’s pro-
tocol [32]. Sub-G1 DNA content was analyzed using a
FACSCalibur flow cytometer (BD Biosciences, Brus-
sels, Belgium).
2.9. Fluorescent microscopy
SW948 cells were seeded in 6-well plate on poly-
L-lysine coated glass cover slides (Sigma-Aldrich
Chemie BV, Zwijndrecht, The Netherlands). Cells pre-
treated or not with LY294002 for 16 h were in-
cubated for 45 min on ice with anti-DR5 antibody
(eBiosciences, via ITK diagnostics BV, Uithoorn, The
Netherlands), diluted 1:100 in ice-cold PBS. After two
washing steps with ice-cold PBS, the cells were incu-
bated with the secondary antibody Alexa Fluor 488-
goat anti-mouse IgG1 (Invitrogen, Molecular probes,
Breda, The Netherlands), diluted 1:200 in ice-cold
PBS for 1 h on ice. Next, cells were either left on ice or
stimulated with 200 nM HGS-TR2J diluted in medium
for 30 min at 37◦C. Cells were then fixated with ice-
cold methanol-acetone (1:1) for 10 min at −20◦C. Af-
ter three washing steps with ice-cold PBS, the cells
were stained for 5 min on ice with Hoechst 33258
(Invitrogen, Molecular Probes, Leiden, The Nether-
lands) diluted 1:10,000 in ice-cold PBS to visualize
the nuclei. After mounting the slides in Vectashield
Mounting medium H-1000 (Vector, via Brunschwig
Chemie, Amsterdam, The Netherlands), analysis was
performed using a Leica fluorescence microscope DM-
RXA.
2.10. Statistical analysis
Data are represented as the mean ± SE. In all cases,
statistical analyses were done using 2-tailed Student’s
t-test. p-Values < 0.05 were considered significant
and are indicated with an asterisk.
3. Results
3.1. IGF-1R inhibition using NVP-AEW541
modulates sensitivity to rhTRAIL and
DR-agonistic antibodies
We evaluated the role of IGF-1R expression and
its inhibition on TRAIL sensitivity using the isogenic
SW948/SW948-TR model. Membrane expression of
IGF-1R was similar in the SW948 cell line and its
TRAIL resistant sub-line SW948-TR (Fig. 1A, B). The
surface levels were not as elevated as those seen in
the MCF7 cells, known to express high levels of IGF-
1R (Fig. 1B). We then incubated the cells with various
concentrations of the IGF-1R inhibitor NVP-AEW541.
Both cell lines showed nanomolar sensitivity to the
compound, with a mean GI40 (concentration inhibiting
cell growth by 40%) below 1 µM in a survival assay
(Fig. 1C).
Cytotoxicity assays with TRAIL or the agonistic
antibodies in combination with NVP-AEW541 were
complicated by the interference of growth inhibitory
effects versus apoptosis-inducing effects. We therefore
focused on the apoptosis-inducing effects of TRAIL
and the agonistic antibodies, using a shorter incuba-
tion time. To compensate for the shorter incubation,
NVP-AEW541 was combined at a concentration cor-
responding to the GI60 with rhTRAIL or the DR-
agonistic antibodies to stimulate apoptosis. Cleavage
of poly-ADP ribose phosphate (PARP) was used to
assess apoptosis in SW948 (Fig. 1D). The untreated
cells and the cells incubated with NVP-AEW541 alone
only exhibited the full form of PARP, indicating that
NVP-AEW541 does not induce apoptosis at the con-
centration used. Upon treatment with rhTRAIL PARP
was fully cleaved into its 89 kDa fragment, reflect-
ing high levels of apoptosis. To study DR4 and DR5-
mediated apoptosis individually, cells were stimulated
with agonistic DR4 (HGS-ETR1) or DR5 antibody
(HGS-TR2J). Similarly to rhTRAIL, HGS-ETR1 was
a very effective inducer of PARP cleavage. HGS-TR2J
also induced PARP cleavage, but only partially, indi-
cating that DR5 was less potent than DR4 in trans-
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Fig. 1. SW948 and SW948-TR cells express surface IGF-1R and inhibition of this receptor modifies sensitivity to death receptor agonists.
(A) Representative example of IGF-1R expression in SW948. Positive receptor expression was detected as an increased fluorescence intensity
of the whole cell population and resulted in a peak-shift to the right (a – control; b – IgG1 and c – IGF-1R). (B) Surface expression of IGF-1R
in SW948, SW948-TR and MCF7 cells (positive control for IGF-1R expression), as determined by flow cytometry. IGF-1R expression is given
as Mean Fluorescent Intensity (MFI), normalized to 100. Values are mean ± SE of at least three independent experiments. (C) Survival (%) of
SW948 and SW948-TR cells after continuous incubation with NVP-AEW541 for 96 h, as measured by cytotoxicity assays. Values are mean ± SD
of at least three independent experiments. (D) Western blot analysis of PARP cleavage in SW948. The cells were pre-incubated for 15–18 h with
5 µM NVP-AEW541, then either left untreated or exposed for 3 additional hours with rhTRAIL (0.1 µg/ml), HGS-ETR1 (50 nM) or HGS-TR2J
(50 nM) before harvest. (Colors are visible in the online version of the article; http://dx.doi.org/10.3233/ACP-CLO-2010-0549.)
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ducing the apoptotic signal. When NVP-AEW541 was
combined with rhTRAIL or HGS-ETR1, the cleav-
age of PARP was unexpectedly lower compared to
rhTRAIL or HGS-ETR1 alone, which suggested that
NVP-AEW541 decreased the sensitivity to these lig-
ands. In contrast, the amount of cleaved PARP was
higher when HGS-TR2J was combined with NVP-
AEW541 in comparison to HGS-TR2J alone, signi-
fying an increase in DR5-mediated apoptosis. Next,
we performed caspase 3/7 enzyme activity assay as an
additional method to assess apoptosis in SW948 and
also in the TRAIL-resistant SW948-TR cells. Incuba-
tion with NVP-AEW541 alone had no effect on cas-
pase 3/7 activation in either cell line (Fig. 2A and B).
Upon inhibition of IGF-1R using NVP-AEW541, the
sensitivity to rhTRAIL decreased by 46.2 ± 11.5%
(mean ± SE) in SW948. Similar findings were done
in SW948-TR cells, which became even more resis-
tant to rhTRAIL (42.6 ± 2% decrease in caspase 3/7
activity after rhTRAIL treatment). IGF-1R inhibition
effectively decreased DR4-mediated caspase 3/7 activ-
ity by 39.8 ± 10.8% in SW948 cells, while SW948-
TR cells followed a similar trend (19.3% decrease
±15.2). In contrast, both cell lines exhibited an in-
crease in DR5-mediated caspase 3/7 activity (an in-
crease of 78.2 ± 5.9% in SW948 and of 92.7 ± 26.7%
in SW948-TR).
Although we do not show a formal concentration-
dependent analysis here, the effects of NVP-AEW541
on DR-mediated apoptosis proved to be concentra-
tion dependent. Concentrations below the GI60 showed
similar, although less pronounced effects, and higher
concentrations of NVP-AEW541 (up to 10 µM) had
even more dramatic effects on DR-mediated apoptosis,
in absence of additional cell death as a single agent.1
3.2. IGF-1R inhibition can modulate processing and
expression of DISC components
The effects of NVP-AEW541 on the protein lev-
els of the components of the death-inducing signal-
ing complex (DISC) were analyzed by Western blot-
ting. NVP-AEW541 did not decrease the basal ex-
pression of procaspase 8, nor did it affect the expres-
sion of fas-associated death domain (FADD) or cellular
Flice inhibitory protein (c-FLIP), in SW948 (Fig. 2C).
Following treatment with rhTRAIL, procaspase 8 was
cleaved into its intermediate (p43/41) and ultimately
active forms (p18). However, after pretreatment with
1Data not shown.
NVP-AEW541, rhTRAIL failed to cause a complete
cleavage of procaspase 8. As expected, c-FLIP was
cleaved after treatment with rhTRAIL. NVP-AEW541
pretreatment did not induce any noticeable change in
the processing of c-FLIP induced by rhTRAIL. Fol-
lowing pretreatment with NVP-AEW541, HGS-ETR1
induced the same pattern of caspase 8 and c-FLIP
cleavage as found with the combination of rhTRAIL
and NVP-AEW541. In contrast, DR5 targeting using
HGS-TR2J alone failed to fully cleave procaspase 8
and c-FLIP. NVP-AEW541 pretreatment enhanced the
responsiveness to HGS-TR2J, triggering almost full
cleavage of both proteins.
Such changes in the apoptotic response could be due
to modulation of the surface expression of DR4 and
DR5. We assessed the effects of NVP-AEW541 on cell
membrane DR4 and DR5 expression in both SW948
and SW948-TR (Fig. 2D). Incubating the cells with
NVP-AEW541 indeed resulted in a downregulation of
membrane DR4. On the other hand, no changes were
observed in DR5 membrane level.
3.3. IGF-1R exerts its effects on TRAIL sensitivity via
the PI3K pathway
Because we expected NVP-AEW541 to influence
DR-mediated apoptosis by inhibiting pathways down-
stream of IGF-1R, we tested whether IGF-1 could in-
duce Akt phosphorylation, and whether NVP-AEW541
was able to inhibit this phosphorylation. Akt is one of
the key proteins phosphorylated by PI3K downstream
of IGF-1R [26]. Cells were serum-starved for 24 h, pre-
treated or not with NVP-AEW541 for one hour at a
concentration neighboring the GI20 of both cell lines,
and finally either left untreated or treated for 15 min
with recombinant human (rh)IGF-1. Concentrations
of rhIGF-1 (10–50 ng/ml) within the physiological
range induced phosphorylation of Akt in both cell lines
(Fig. 3A). Pretreatment with NVP-AEW541 dramati-
cally reduced IGF-1-induced phosphorylation of Akt
in both cell lines. Total Akt levels were similar in the
two cell lines and were not affected by NVP-AEW541
or rhIGF-1. Phospho-MAPK44/42 (pMAPK44/42) lev-
els were studied as this protein can also be activated
by phosphorylation in response to IGF-1. The levels
of MAPK44/42 and pMAPK44/42 were similar with and
without NVP-AEW541 treatment, suggesting that the
activity of this pathway might be independent of IGF-1
in these cells.2 We then decided to investigate whether
2Data not shown.
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Fig. 2. IGF-1R inhibition modulates DR-mediated apoptosis and downregulates surface DR4 expression. Modulation of rhTRAIL or agonis-
tic antibody induced apoptosis by NVP-AEW541 in SW948 (A) and SW948-TR (B), as assessed by caspase 3/7 activity assay. Cells were
pre-incubated for 15–18 h with 5 µM NVP-AEW541, then either left untreated or exposed to rhTRAIL (0.1 µg/ml), HGS-ETR1 (50 nM) or
HGS-TR2J (50 nM) for 3 additional hours before harvest. Caspase 3/7 activity is expressed in arbitrary units (a.u.), as the ratio of caspase 3/7
activity in treated cells to untreated cells. Values are mean ± SE of at least three independent experiments. (C) Western blot analysis of the
expression levels of several proteins located downstream from the TRAIL receptors, after IGF-1R inhibition and treatment with rhTRAIL or
agonistic DR antibody, in SW948. The cells were pre-incubated for 15–18 h with 5 µM NVP-AEW541, then either left untreated or exposed
for 3 additional hours with rhTRAIL (0.1 µg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) before harvest. (D) Surface expression of TRAIL
receptors in SW948 and SW948-TR, in control cells and after 15–18 h exposure to 5 µM NVP-AEW541.
236 B. Pennarun et al. / Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells via DR5
Fig. 3. PI3K mediates the effects of IGF-1R inhibition on DR-mediated apoptosis. (A) Western blot analysis showing inhibition of IGF-1-induced
Akt phosphorylation by NVP-AEW541 in SW948 and SW948-TR. Cells were pretreated for 1 h with 5 µM NVP-AEW541 before treatment
with increasing concentrations of rhIGF-1 and subsequent harvesting. (B) Western blot analysis showing inhibition of Akt phosphorylation
by LY294002 in SW948 and SW948-TR. Cells grown in medium with FCS were treated or not for 1 h with increasing concentrations of
LY294002 before harvest. (C) Modulation of rhTRAIL or agonistic antibody induced apoptosis by PI3K inhibition in SW948, as assessed by
caspase 3/7 activity assay in SW948. Cells were pre-incubated for 15–18 h with 20 µM LY294002, then either left untreated or exposed to
rhTRAIL (0.1 µg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) for 3 additional hours before harvest. (C) Caspase 3/7 activity assay in SW948
cells. Cells were pre-incubated for 15–18 h with 20 µM LY294002, then either left untreated or exposed to rhTRAIL (0.1 µg/ml), HGS-ETR1
(50 nM) or HGS-TR2J (50 nM) for 3 additional hours before harvest. (D) Western blot analysis of PARP cleavage in SW948. The cells were
pre-incubated for 15–18 h with 20 µM LY294002, then either left untreated or exposed for 3 additional hours with rhTRAIL (0.1 µg/ml),
HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) before harvest. (E) Caspase 3/7 activity assay in SW948-TR. Cells were treated as described in (C).
a specific PI3K inhibitor could also inhibit Akt phos-
phorylation in SW948 and SW948-TR cells. As seen in
Fig. 3B, upon treatment with 10–20 µM LY294002 for
1 h, Akt phosphorylation in both cell lines was inhib-
ited in a concentration-dependent manner. LY294002
had no effects on total Akt expression levels.
Next, LY294002 was combined with rhTRAIL
or death receptor-specific antibodies. Treatment of
SW948 cells with LY294002 alone did not affect apop-
tosis, as measured by caspase 3/7 activity (Fig. 3C).
HGS-ETR1-induced caspase 3/7 activity was reduced
by 27.6 ± 8.2%. Although there was only a non-
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significant trend, rhTRAIL-induced caspase 3/7 ac-
tivity decreased when the cells were pretreated with
LY294002 (by 14.7 ± 9.8%). In contrast, sensitivity
through DR5 was clearly increased by 107.8 ± 38.5%.
Analysis of PARP cleavage confirmed the changes in
susceptibility to these agents in SW948 (Fig. 3D).
In SW948-TR (Fig. 3E), LY294002 similarly de-
creased sensitivity to rhTRAIL (by 38.3 ± 0.6%), as
assessed by caspase 3/7 activity measurement. Al-
though these differences were not statistically signifi-
cant, pretreatment with LY294002 lowered sensitivity
to HGS-ETR1 (by 32.3 ± 10.3%) but increased HGS-
TR2J sensitivity (41.2 ± 14.7% increase).
3.4. PI3K inhibition modulates caspase 8 and c-FLIP
cleavage
We examined whether LY294002 induced similar
effects to NVP-AEW541 at the level of the DISC pro-
teins. The results for caspase 8 were similar to those
previously seen using NVP-AEW541, albeit the in-
hibition of procaspase 8 processing to the intermedi-
ate and active forms upon rhTRAIL and HGS-ETR1
seemed less strong (Fig. 4A). Basal c-FLIP and FADD
levels were not affected by LY294002. The changes
in c-FLIP cleavage after LY294002 exposure followed
the pattern seen after NVP-AEW541 treatment, al-
though the loss of c-FLIP through cleavage upon HGS-
ETR1 or HGS-TR2J treatment after LY294002 was
slightly higher.
Next, we studied whether inhibiting PI3K would
modulate death receptor expression at the cell surface,
as seen with NVP-AEW541. As expected, LY294002
downregulated DR4 to the level of DR5 in SW948 and
SW948-TR, providing an explanation for the reduction
in rhTRAIL sensitivity (Fig. 4B).
Localization of the death receptors is known to be
modulated by certain drugs which cause them to ag-
gregate and thereby increase their sensitivity to death
inducing ligands [35]. This prompted us to exam-
ine whether the distribution of DR5 at the cell sur-
face was affected by PI3K inhibition. Fluorescent mi-
croscopy imaging of membrane DR5 in SW948 cells
did not show any change in DR5 distribution at the
cell surface following treatment with 20 µM LY294002
Fig. 4. PI3K inhibition modulates DISC proteins cleavage and surface DR4 levels, but not cell membrane localization of DR5 or initial DR5-DISC
formation. (A) Expression levels of several proteins located downstream of the TRAIL receptors were determined by Western blotting in SW948.
The cells were pre-incubated for 15–18 h with 20 µM LY294002, then either left untreated or exposed for 3 additional hours with rhTRAIL
(0.1 µg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) before harvest. (B) Surface expression of TRAIL receptors in SW948 and SW948-TR,
in control cells and after 15–18 h exposure to 20 µM LY294002. Receptor expression was detected as the average antigenic density of the whole
cell population (Black line histograms: fluorescence of the untreated cells, grey shaded histograms: fluorescence of the cells treated with 20 µM
LY294002 for 15–18 h). (C) Fluorescent microscopy imaging of DR5 in SW948 cells in untreated cells and cells exposed with 20 µM LY294002
for 17 h, stimulated or not with HGS-TR2J for 15 min. Cells were first pretreated with LY294002 and stained for cell membrane DR5. Next,
cells were either kept on ice or treated with HGS-TR2J for 15 min at 37◦C before fixation. One representative of at least three independent
experiments is shown. (D) DR5-DISC immunoprecipitation in SW948 cells, using the HGS-TR2J antibody. Cells were pretreated or not for 17 h
with 20 µM LY294002 before stimulation for 15 min using HGS-TR2J and immunoprecipitation with protein G agarose (C – antibody added
after cell lysis, T – cells treated with HGS-TR2J). DR5-DISC analysis was performed at least three times. (Colors are visible in the online version
of the article; http://dx.doi.org/10.3233/ACP-CLO-2010-0549.)
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Fig. 4. (Continued.)
(Fig. 4C). Because differences in DR5 aggregation
following LY294002 treatment might only occur af-
ter stimulation of the receptor, we stimulated DR5 for
30 min using HGS-TR2J. As seen in Fig. 4C, DR5
aggregated following stimulation with HGS-TR2J, but
the staining pattern was similar between LY294002-
treated and untreated cells.
Since PI3K inhibition increased caspase 8 acti-
vation, suggesting modifications in DR5-DISC for-
mation, we performed a co-immunoprecipitation of
this complex using HGS-TR2J, with or without pre-
incubation with LY294002. To our surprise, DISC for-
mation was comparable for both stimuli (Fig. 4D).
HGS-TR2J could recruit DR5, FADD, caspase 8 and
c-FLIP. In control cells, three caspase 8 forms were
detected in the DR5-DISC: the full form, the inter-
mediate p43/41 cleaved form and the p26/24 cleavage
product. The latter indicates full cleavage of caspase
8 and therefore release of active caspase 8 from the
complex. c-FLIP was mostly present in its intermediate
form. In cells pretreated with LY294002, the ratio of
each DISC component was similar. No DR4 was found
in the DR5-DISC complex, in both LY294002-treated
and -untreated cells.3 Later time points (up to 1 h,
when active caspase 8 becomes detectable in whole
cell lysates from LY294002-pretreated cells) displayed
similar DISC content.4 Thus, the relative proportion of
each DISC protein in the DR5-DISC is similar with
and without LY294002.
3.5. The opposite effects on DR4- and DR5-sensitivity
induced by PI3K signaling pathway inhibition
are not specific to the SW948/SW948-TR
isogenic model
To expand our results to a non-isogenic model, we
also assessed the effects of PI3K-specific inhibition
with LY294002 on TRAIL receptor-mediated apopto-
sis in Colo205. These cells were initially highly sensi-
3Data not shown.
4Data not shown.
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tive to rhTRAIL and to the DR5-targeting antibody and
less to the DR4-targeting antibody, indicating that here
DR5 was the most potent of the two death receptors.
We therefore used concentrations of 50 nM for HGS-
ETR1 and 5 nM for HGS-TR2J to induce equivalent
amounts of apoptosis via each death receptor. Our re-
sults show that LY294002 treatment decreased sensi-
tivity to rhTRAIL and HGS-ETR1 (Fig. 5A). Impor-
tantly, DR5-mediated sensitivity increased following
LY294002 treatment, as seen in SW948 and SW948-
TR. Moreover, Colo205 cells also exhibited a reduc-
tion in surface membrane DR4 after PI3K inhibition,
as seen in SW948 and SW948-TR (Fig. 5B).
4. Discussion
Prosurvival signals originating from growth factor
receptors, including IGF-1R, prevent cell death in-
duced by radiation, cytotoxic drugs and members of
the tumor necrosis factor family [18,30,41,52]. In the
present study, we demonstrated that inhibition of pro-
survival signaling using the IGF-1R inhibitor NVP-
AEW541 exclusively increased sensitivity to DR5-
mediated apoptosis in SW948 and SW948-TR colon
carcinoma cells. SW948 cells in particular were ini-
tially very sensitive via DR4, and therefore contained
all the proteins necessary to form a DISC, but they
exhibited significant resistance to apoptosis mediated
via DR5. The IGF-1R inhibitor exclusively released
the blockade of caspase 8 cleavage at the level of
DR5. The TRAIL-resistant cell line SW948-TR be-
came more sensitive to the anti-DR5 agonistic anti-
body, suggesting that the effects of IGF-1R inhibi-
tion are not restricted to rhTRAIL-sensitive cells. Sur-
prisingly, we found that IGF-1R inhibition decreased
sensitivity to rhTRAIL or an anti-DR4 agonistic an-
tibody. The decrease in sensitivity to rhTRAIL and
to the anti-DR4 antibody could be explained in part
by the ∼50% downregulation of membrane DR4 fol-
lowing IGF-1R inhibition seen in all three cell lines.
We correlated this DR4 downregulation with a de-
crease in caspase 8 cleavage following rhTRAIL or
anti-DR4 treatment. This surprising decrease in sensi-
tivity to some DR-ligand is supported by prior demon-
strations that inhibition of oncogenic pathways such
as HER-2 and Ras also reduces the expression of
TRAIL receptors, as well as their sensitivity [10,11].
Mahalingam et al. recently found that inhibition of the
c-Jun N-terminal kinase (JNK) stress pathway antag-
onized TRAIL-induced apoptosis but stimulated anti-
DR antibody-induced apoptosis in several colon can-
cer cells [29]. Likewise, a proapoptotic effect of IGF-1
on rhTRAIL sensitivity in 6 out of 9 colon cancer cell
lines was described [38]. We identified PI3K as the me-
diator of both DR4 decrease and DR5 increase in sen-
sitivity to their respective agonist antibodies. We show
that an IGF-1R inhibitor, at the concentration used,
successfully prevented PI3K-dependent Akt phospho-
rylation induced by physiologically relevant levels of
soluble IGF-1. This was accompanied by strong effects
on DR-mediated apoptosis. Similar results were seen
on Akt phosphorylation and DR-mediated apoptosis
using the widely-accepted PI3K inhibitor LY294002,
which further supports the role for PI3K in modulating
DR-mediated apoptosis. Thus, as depicted in Fig. 6,
our experiments provide a link between the involve-
ment of IGF-1R in PI3K/Akt activity in colon cancer
cells and the role of this pathway in death receptor-
mediated apoptosis regulation.
We investigated several hypotheses for the increase
in DR5-mediated sensitivity following PI3K inhibi-
tion. No change in membrane DR5 expression was
seen. It has been reported that active PI3K can directly
act on the DISC and interfere with caspase 8 cleav-
age by up-regulating c-FLIP [33]. We found that nei-
ther basal levels of c-FLIP nor DR5-DISC c-FLIP lev-
els were altered by the PI3K inhibitor in SW948 cells.
This indicates that the effects of PI3K on the DR5-
DISC are independent of c-FLIP in our model. Simi-
lar observations were made regarding the basal levels
of other proteins recruited to the DISC. Furthermore,
we also excluded that sensitivity to the anti-DR5 anti-
body following PI3K inhibition increases was caused
by receptor aggregation. A number of proteins identi-
fied as downstream substrates of PI3K/Akt can mod-
ulate the mitochondrial apoptotic pathway of apopto-
sis, for instance caspase 9 and Bad [3,8,9]. Inhibition
of caspase 9 activity using zLEHD-fmk did not protect
SW948 cells from apoptosis induced by either TR2J
or the combination of TR2J with LY294002, point-
ing toward a mitochondria-independent mechanism.5
Following LY294002 treatment, both caspase 8 and c-
FLIP cleavage was enhanced upon stimulation of DR5
with its agonistic antibody, which strongly supports the
existence of a sensitizing mechanism at the DR5-DISC
itself. We suggest that PI3K inhibition leads to a higher
turn-over of c-FLIP and caspase 8 at the DR5-DISC,
thus gradually increasing the amount of their cleaved
cytoplasmic forms.
5Results not shown.
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Fig. 5. The effects of PI3K inhibition on DR-mediated apoptosis can also be seen in cells that are already more sensitive to HGS-TR2J than
to HGS-ETR1 initially. (A) Sub-G1 content analysis in Colo205. Cells were pre-incubated for 15–18 h with 20 µM LY294002, then either left
untreated or exposed to rhTRAIL (0.1 µg/ml), HGS-ETR1 (50 nM) or HGS-TR2J (50 nM) for 3 additional hours before harvest. Nuclear DNA
was then stained with propidium iodide and the cells analyzed by flow cytometry. The value in percent indicates the amount of apoptosis as
measured by the count of sub-G1 events. One representative of at least 3 independent experiments is shown. (B) Surface expression of TRAIL
receptors in Colo205, in untreated cells and after 15–18 h exposure to 20 µM LY294002. Receptor expression is measured as Mean Fluorescent
Intensity (MFI) normalized to 100.
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Fig. 6. Model for differential modulation of TRAIL receptor ligand-induced apoptosis by IGF-1R/I3K-dependent mechanisms. TRAIL recep-
tor-specific agonists bind to their cognate TRAIL death receptor trimers, stimulating the TRAIL receptor-mediated apoptosic pathway. In this
figure, DR4 and DR5 specifically designate homotrimers, while DR4/DR5 refers to either type of trimer, including possible heterotrimers. Upon
activation of IGF-1R by growth factors such as IGF-1, the receptor becomes autophosphorylated, which activates PI3K. Active PI3K triggers
Akt phosphorylation and its subsequent activation. Inhibition of PI3K using LY294002 or inhibition of IGF-1R-induced PI3K activation us-
ing NVP-AEW541 leads to a decrease in Akt phosphorylation. This is also accompanied by inhibition of TRAIL- and agonistic DR4 anti-
body-induced apoptosis, notably due to a decrease in membrane DR4 expression and decreased caspase 8 cleavage. Conversely, caspase 8 cleav-
age and apoptosis induced by agonistic DR5 antibody are increased when IGF-1R or PI3K are inhibited using NVP-AEW541 or LY294002,
respectively. (Colors are visible in the online version of the article; http://dx.doi.org/10.3233/ACP-CLO-2010-0549.)
In Colo205, which is a DR5-driven cell line with
regard to the relative potency of each DR to trans-
duce apoptosis [42], sensitivity to the DR5 antibody
was remarkably enhanced by LY294002. Conversely,
DR4-mediated sensitivity was almost completely lost
and sensitivity to rhTRAIL decreased by ∼50%. Al-
though the downregulation of DR4 could explain part
of these effects, the benefits of PI3K inhibition on
DR5 signaling seemed restricted to the DR5 anti-
body but not to rhTRAIL. Thomas et al. established
[40] that the cytoplasmic tail of DR4 and DR5 had
an important role in facilitating FADD binding and
DISC formation upon stimulation with DR-ligands.
Depending on this cytoplasmic tail, the ability of the
various DR-ligands to trigger apoptosis differed. Un-
like TRAIL, the anti-DR5 agonistic antibody HGS-
ETR2 could induce apoptosis independently of the last
c-terminal amino-acids of DR5. In view of these find-
ings, we suggest that PI3K inhibition might induce
intracellular conformational changes at the level of
DR5 that only benefits to HGS-TR2J. Recently, Has-
san et al. described how inhibition of the apoptosis
signal-regulating kinase 1 (ASK1)-JNK/p38 pathway
prevented caspase 8 cleavage in response to the agonis-
tic anti-Fas antibody CH11, notably via inhibition of
CH11-induced FADD phosphorylation [16]. It is pos-
sible that such FADD phosphorylation mechanism dif-
ferentially modulates the response to TRAIL and to
the various DR agonistic antibodies. Numerous pro-
teins can be recruited to DR4 and DR5 and modulate
apoptosis signalling [35]. Our study supports the exis-
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tence of pathways with opposite effects for the various
TRAIL receptor ligands.
Since PI3K is an essential component in the trans-
duction of survival signals originating from the growth
factor receptors, we consider a better understanding of
its influence on the TRAIL pathway necessary. Inter-
estingly, while chemotherapy requires the p53 gene to
upregulate DR5 and thereby increase death ligand sen-
sitivity in colonic carcinoma [47], PI3K inhibition im-
proved DR5-mediated sensitivity without requiring a
functional p53 (the three cell lines used in our experi-
ments express mutant p53). Elucidating the mechanism
of action of PI3K on DR5 could therefore be decisive
for future DR agonist-based therapies, since the vast
majority of CRC cancers carry mutations in p53. Con-
versely, inhibition of PI3K combined with chemother-
apy might further improve sensitivity to DR5 agonists.
DR4 and DR5 can be targeted individually (using
antibodies or death-receptor specific forms of TRAIL)
or simultaneously (using rhTRAIL), and these ligands
will have to be combined with other therapies to over-
come resistance mechanisms. We conclude that DR5-
targeting agents, such as agonistic antibodies, might be
optimal to elicit maximum cell death induction from
DR agonist-based regimens combined with drugs in-
hibiting PI3K. Our results also suggest caution re-
garding possible antagonist effects when combining
rhTRAIL or DR4 agonistic antibodies with IGF-1R or
PI3K inhibitors.
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